Summit plunges 35%; partner Akesso wins FDA nod for cancer drug

Shares of Summit Therapeutics ( NASDAQ: SMMT ) ended five straight sessions of gains on Friday as the stock lost ~35% , triggering a trading halt, a day after the FDA approved its partner Akeso’s ( OTCPK:AKESF ) first internally developed medicine. Over 11.7M shares of.